Form 4 for AUPH Aurinia Pharmaceuticals Inc.
Accepted 2021-11-03 00:00:00 ET · period of report 2021-11-01 · accession 0001628280-21-021477 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-03 | 2021-11-01 | AUPH | Martin Michael Robert | Chief Business Off | S - Sale+OE | $31.64 | -45.0K | 176.9K | -20% | -$1.42M |
| D | 2021-11-03 | 2021-11-01 | AUPH | Martin Michael Robert | Chief Business Off | M - OptEx | $3.20 | +45.0K | 221.9K | +25% | +$144.0K |
| D | 2021-11-03 | 2021-11-01 | AUPH | Martin Michael Robert | Chief Business Off | M - OptEx | $0.00 | -45.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-01 | S | D | 45,000 | $31.64 | 176,861 | D | — | — | (F3) The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $31.50 to $31.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 2 | Common | Common Stock | 2021-11-01 | M | A | 45,000 | $3.20 | 221,861 | D | — | — | (F1) Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. |
| 3 | Derivative | Stock Option (right to buy) | 2021-11-01 | M | D | 45,000 | $0.00 | 0 | D | $3.20 · — to 2027-02-09 | 45,000 Common Stock | (F1) Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. (F4) The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date. |